This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII

Charlotte L. Mentzel, MD; P. Roberto Bakker, MD, PhD; Jim van Os, MD, PhD; Marjan Drukker, PhD; Glenn E. Matroos, MD, PhD; Hans W. Hoek, MD, PhD; Marina A. J. Tijssen, MD, PhD; and Peter N. van Harten MD, PhD

Published: March 29, 2017

Article Abstract

Objective: To test the efficacy of current treatment recommendations for parkinsonism and tardive dyskinesia (TD) severity in patients with severe mental illness (SMI).

Methods: We present an 18-year prospective study including all 223 patients with SMI (as defined by the 1987 US National Institute of Mental Health, which were based on DSM-III-R diagnostic criteria) receiving care from the only psychiatric hospital of the former Netherlands Antilles. Eight clinical assessments (1992-2009) focused on movement disorders and medication use. Tardive dyskinesia was measured by the Abnormal Involuntary Movement Scale and parkinsonism by the Unified Parkinson’s Disease Rating Scale. Antipsychotics were classified into first-generation antipsychotic (FGA) versus second-generation antipsychotic (SGA) and high versus low dopamine 2 (D2) affinity categories. The effect that switching has within each category on subsequent movement scores was calculated separately by using time-lagged multilevel logistic regression models.

Results: There was a significant association between reduction in TD severity and starting/switching to an FGA (B = 3.54, P < .001) and starting/switching to a high D2 affinity antipsychotic (B = 2.49, P < .01). Adding an SGA to existing FGA treatment was associated with reduction in TD severity (B = 2.43, P < .01). For parkinsonism, stopping antipsychotics predicted symptom reduction (B = 7.76, P < .01 in FGA/SGA-switch model; B = 7.74, P < .01 in D2 affinity switch model), while starting a high D2 affinity antipsychotic predicted an increase in symptoms (B = 3.29, P < .05 in D2 affinity switch model).

Conclusions: The results show that switching from an FGA to an SGA does not necessarily result in a reduction of TD or parkinsonism. Only stopping all antipsychotics reduces the severity of parkinsonism, and starting an FGA or a high D2 affinity antipsychotic may reduce the severity of TD.

Related Articles

Volume: 78

Quick Links: